Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2023.0056
Abstract: Importance Preclinical data about the synergistic activity of radiotherapy (RT) and trabectedin have been reported. The combination of trabectedin and RT in treating myxoid liposarcomas appears worth exploring. Objective To explore the effectiveness and safety… read more here.
Keywords: nonrandomized clinical; myxoid liposarcoma; trabectedin; clinical trial ... See more keywords
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.06.018
Abstract: OBJECTIVE Trabectedin demonstrated significantly improved disease control in leiomyosarcoma and liposarcoma patients in a global phase 3 trial (NCT01343277). A post hoc analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine… read more here.
Keywords: trabectedin dacarbazine; trabectedin; efficacy safety; analysis ... See more keywords
Impact of relative dose intensity of trabectedin with pegfilgrastim support: a single-centre retrospective study.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2022.2164116
Abstract: Relative dose intensity (RDI) has been associated with improved survival in patients with advanced solid tumours. However, there is no evidence regarding RDI in patients under long-term treatment with trabectedin for adult advanced soft tissue… read more here.
Keywords: dose intensity; relative dose; trabectedin; pegfilgrastim ... See more keywords
Abstract LB-047: Optimizing the trabectedin-mediated inhibition of EWS-FLI1 activity by schedule and fusion type
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-lb-047
Abstract: BACKGROUND: Ewing sarcoma (ES) is a pediatric malignancy characterized by the EWS-FLI1 transcription factor. ES tumors require the continuous transcriptional activity of EWS-FLI1 for the oncogenic phenotype, regardless of fusion type, which makes EWS-FLI1 an… read more here.
Keywords: ews fli1; trabectedin; schedule; type ... See more keywords
Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.11547
Abstract: 11547Background: Trabectedin (T) is an established option as monotherapy for advanced soft tissue sarcomas (STS; Leiomyosarcomas and Liposarcomas in the USA) and in combination with pegylated lipos... read more here.
Keywords: cardiac safety; trabectedin; safety trabectedin; combination pegylated ... See more keywords
The Role of Trabectedin in Soft Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.777872
Abstract: Background: Systemic chemotherapy for advanced disease is another therapeutic option in the management of metastases in soft tissue sarcoma (STS). Doxorubicin either alone or in combination with ifosfamide has been used as first-line chemotherapy. Furthermore,… read more here.
Keywords: chemotherapy; tissue sarcoma; line; first line ... See more keywords
Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12123647
Abstract: Simple Summary Trabectedin is a cytotoxic drug used for the treatment of advanced soft tissue sarcoma. One of the most frequent side effects is hepatotoxicity, which occurs in nearly 40% of patients. In this pharmacogenetic… read more here.
Keywords: tissue sarcoma; advanced soft; soft tissue; trabectedin ... See more keywords
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14051290
Abstract: Simple Summary Trabectedin is an FDA-approved chemotherapy with demonstrated benefit for some sarcoma subtypes, particularly in the metastatic setting. Although some patients receiving trabectedin have only modest benefit, other patients are exceptional responders. While several… read more here.
Keywords: analysis; expression; immunologic gene; gene ... See more keywords
Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms232214305
Abstract: Trabectedin is used for the treatment of advanced soft tissue sarcomas (STSs). In this study, we evaluated if trabectedin could enhance the efficacy of irradiation (IR) by increasing the intrinsic cell radiosensitivity and modulating tumor… read more here.
Keywords: cell; effect; soft tissue; following trabectedin ... See more keywords